M27-A2. 3 Yeast inocula were diluted to a final concentration of 0.5 -2.5 Â 10 3 cfu/mL. From optically clear wells, 10 mL was withdrawn and plated on Sabouraud dextrose agar for the determination of MFC. Plates were incubated at 358C for 72 h. MFC was defined as the lowest drug concentration that yielded less than three colonies, a killing activity of $99%.
For statistical analysis, the Wilcoxon rank-sum test was used using SPSS 14.0 for Windows (SPSS Inc., Chicago, IL, USA), with significance being set at P , 0.05.
Results of the study confirmed that MICs for the two quality control Candida isolates were within the limits described in the M27-A2 document.
3 Table 1 shows MIC 50 and MFC 50 values, geometric means and ranges of the three azoles.
Statistical analysis revealed no significant differences between MICs of posaconazole and voriconazole. However, highly significant differences were found between fluconazole MICs and those of the other two azoles (P , 0.001). The MICs for the two Cryptococcus species were compared; they were found to be significantly higher for C. gattii than for C. neoformans (P ¼ 0.007), especially the MICs of fluconazole. The MFCs of fluconazole and voriconazole were higher for C. gattii serotype B. In contrast, the MFCs of posaconazole were lower, only 2 mg/L for one C. neoformans serotype A isolate and one C. gattii serotype B isolate. The MFCs of voriconazole were higher: !1 mg/L for 4 C. neoformans isolates and !2 mg/L for 11 C. gattii serotype B isolates (44%). The highest MFCs were 2 mg/L for posaconazole, 4 mg/L for voriconazole and 16 mg/L for fluconazole.
Several cases of C. neoformans isolates exhibiting marked reduction in susceptibility to fluconazole have been reported in AIDS patients. 4 Diverse authors attributed the increase in resistance to the widespread use of maintenance therapy with fluconazole. Other studies have reported the opposite trend. The antifungal susceptibility of 70 Spanish C. neoformans clinical isolates did not change significantly between 1994 -96 and 1997 -2005. The fluconazole MIC 50 values remained stable, and the authors concluded that the in vitro resistance to fluconazole decreased over the 11 years. 5 Pfaller et al. 2 examined a large series of strains from 100 medical institutions and reported an accumulative percentage of 99% for isolates inhibited by voriconazole or posaconazole: 99% of the isolates being susceptible at MIC 1 mg/L. Although the authors did not discriminate between C. neoformans and C. gattii, presumably the majority of isolates were C. neoformans.
We have found a very low level of resistance of Cryptococcus species to azoles. The highest MICs were obtained for C. gattii serotype B; this species appeared to be less susceptible to the azoles than both serotypes (A and D) of C. neoformans (P ¼ 0.007 for MIC and P ¼ 0.020 for MFC). MFCs could be better predictors of clinical response to antifungal therapy; however, standard methods have not been developed. Most investigators follow the proposals of Espinel-Ingroff et al. 6 Greater differences in MFCs than MICs were seen; 2 isolates of C. gattii had MFCs of fluconazole !16 mg/L and 13 isolates had MFCs of voriconazole !2 mg/L.
The possibility of change for in vitro susceptibility of Cryptococcus spp. in the future justifies the need for further systematic studies using standardized techniques. This is particularly valid for azoles, as their period of clinical and therapeutic use is still very short. 
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